维普期刊资源整合服务平台（V6.5）

26篇 您的检索式：作者名="Talpur R"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Phase II evaluation of gemc- itabine monotherapy for cutaneous T-cell lymphoma显示文摘	Duvic M1 Talpur R Wen S	2006	Clin Lym- phoma Myeloma2006，7，1：	1
2	Overall survival in erythrodermic cutaneous T-celllymphoma:an analysis of prognostic factors in a co-hort of patients with erythrodermic cutaneous T-celllymphoma显示文摘	VIDULICH K A TALPUR R BASSETT R L etal	2009	Int J Dermatol2009，48，：	1
3	Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma显示文摘	Duvic M Chiao N Talpur R		0，，4：	1
4	Treatment of cuta - neous T cell lymphoma:cttrrent status and future directions 显示文摘	APISARNTHANARAX N TALPUR R DUVIC M	2002	Am J Clin Dermatol2002，3，3：	1
5	Adsorption of methyl parathion pesticide from water using watermelon peels as a low cost adsorbent显示文摘	MEMON G Z BHANGER M I AKHTAR M TALPUR F N MEMON J R	2008	Chemical Engineering Journal2008，138，13：	1
6	Optimizing bexarotene therapy for cutaneous T - cell lymphoma 显示文摘	Talpur R Ward S Apisarnthanarax N	2002	J Am Acad Dermatol2002，47，5：	1
7	Phase II trial of oral wrinostat (suberoylanitide hydroxamic acid ,SAHA) for refractory cutaneous T-cell lymphoma(CTCL) 显示文摘	VDuvic M Talpur R Ni X	2007	Blood2007，109，1：	1
8	CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma显示文摘	Talpur R Jones DM Alencar AJ	2006	J Invest Dermatol2006，126，3：	1
9	Phase 2 trial of oral vorinostat (suberoylanilide hydroxamlc acid, SAHA) for refractory cuta- neous T-cell lymphoma(CTCL)显示文摘	Duvic M Talpur R Ni X	2007	Blood2007，109，1：	1
10	Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox(ONTAK)显示文摘	Talpur R Apisamthanrax N Ward S	2002	Leuk Lymphoma2002，43，：	1
11	Phase Ⅱ trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma(CTCL)显示文摘	Duvic M Talpur R Ni X	2007	Blood2007，109，：	1
12	Optimizing denileukin diftitox (Ontak) therapy 显示文摘	Duvie M Talpur R	2008	Future Oncol2008，4，4：	1
13	Treatment of cutaneous T cell Lymphoma:current status and future directions显示文摘	Apisarnthanarax N Talpur R Duvic M	2002	Am J Clin Dermatol2002，3，3：	1
14	Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) 显示文摘	DUVIC M TALPUR R NI X	2007	Blood2007，109，1：	1
15	Long-term complete re- sponses to combination therapies and allogeneic stem cell trans- plants in patients with SOzaxy syndrome 显示文摘	Polansky M Talpur R Daulat S	2015	Clin Lymphoma Myeloma Lenk2015，15，5：	1
16	Phase 2 trial of oral vorinostat (suber- oylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)显示文摘	Duvic M Talpur R Ni X	2007	Blood2007，209，1：	1
17	Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application显示文摘	Duvic M Ni X Talpur R	2003	J Invest Dermatol2003，121，4：	1
18	Phase 2 trial of oral vorinostat ( suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma(CTCL) 显示文摘	DUVIC M TALPUR R NI X	2007	Blood2007，109，1：	1
19	Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lym- phomas显示文摘	Talpur R Duvic M	2012	Clin Lymphoma Myeloma Leuk2012，12，3：	1
20	Phase 2 trial of oral vorinostat ( sube- roylanilide hydroxamic acid, SAHA ) for refractory cutaneous T-cell lymphoma(CTCL) 显示文摘	Duvic M Talpur R Ni X	2007	Blood2007，109，1：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示